|
1）Vincent JL, Rello J, Marshall J, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009; 302: 2323-9
|
|
|
|
2）Sorensen TI, Nielsen GG, Andersen PK, et al. Genetic and environmental influences on premature death in adult adoptees. N Engl J Med. 1988; 318: 727-32
|
|
|
|
|
|
3）Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med. 2008; 36: 296-327
|
|
|
|
|
|
4）Cohen J. The immunopathogenesis of sepsis. Nature. 2002; 420: 885-91
|
|
|
|
|
|
5）van der Poll T, Jansen J, Endert E, et al. Noradrenaline inhibits lipopolysaccharide-induced tumor necrosis factor and interleukin 6 production in human whole blood. Infect Immun. 1994; 62: 2046-50
|
|
|
|
|
|
6）Sanders VM, Straub RH. Norepinephrine, the beta-adrenergic receptor, and immunity. Brain Behav Immun. 2002; 16: 290-332
|
|
|
|
|
|
7）Usmani OS, Ito K, Maneechotesuwan K, et al. Glucocorticoid receptor nuclear translocation in airway cells after inhaled combination therapy. Am J Respir Crit Care Med. 2005; 172: 704-12
|
|
|
|
|
|
8）Hancox RJ. Interactions between corticosteroids and beta2-agonists. Clin Rev Allergy Immunol. 2006; 31: 231-46
|
|
|
|
|
|
9）Taylor DR, Hall IP. ADRB2 polymorphisms and beta2 agonists. Lancet. 2007; 370: 2075-6
|
|
|
|
|
|
10）Lanfear DE, Jones PG, Marsh S, et al. Beta2-adrenergic receptor genotype and survival among patients receiving beta-blocker therapy after an acute coronary syndrome. JAMA. 2005; 294: 1526-33
|
|
|
|
|
|
11）Dishy V, Sofowora GG, Xie HG, et al. The effect of common polymorphisms of the beta2-adrenergic receptor on agonist-mediated vascular desensitization. N Engl J Med. 2001; 345: 1030-5
|
|
|
|
|
|
12）Oostendorp J, Postma DS, Volders H, et al. Differential desensitization of homozygous haplotypes of the beta2-adrenergic receptor in lymphocytes. Am J Respir Crit Care Med. 2005; 172: 322-8
|
|
|
|
|
|
13）Nakada TA, Russell JA, Boyd JH, et al. beta2-Adrenergic receptor gene polymorphism is associated with mortality in septic shock. Am J Respir Crit Care Med. 2010; 181: 143-9
|
|
|
|
|
|
14）Landry DW, Levin HR, Gallant EM, et al. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation. 1997; 95: 1122-5
|
|
|
|
|
|
15）Russell JA, Walley KR, Singer J, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med. 2008; 358: 877-87
|
|
|
|
|
|
16）Schmieder RE, Hilgers KF, Schlaich MP, et al. Renin-angiotensin system and cardiovascular risk. Lancet. 2007; 369: 1208-19
|
|
|
|
|
|
17）Mehta PK, Griendling KK. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol. 2007; 292: C82-97
|
|
|
|
|
|
18）Nakada TA, Russell JA, Boyd JH, et al. Association of angiotensin II type 1 receptor-associated protein gene polymorphism with increased mortality in septic shock. Crit Care Med. 2011; 39: 1641-8
|
|
|
|
|
|
19）Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity. 2011; 34: 637-50
|
|
|
|
|
|
20）Thair SA, Walley KR, Nakada TA, et al. A single nucleotide polymorphism in NF-kappaB inducing kinase is associated with mortality in septic shock. J Immunol. 2011; 186: 2321-8
|
|
|
|
|
|
21）Toubiana J, Courtine E, Pene F, et al. IRAK1 functional genetic variant affects severity of septic shock. Crit Care Med. 2010; 38: 2287-94
|
|
|
|
|